IL22646A - 21-esters of pregnane derivatives and a process for their preparation - Google Patents
21-esters of pregnane derivatives and a process for their preparationInfo
- Publication number
- IL22646A IL22646A IL22646A IL2264664A IL22646A IL 22646 A IL22646 A IL 22646A IL 22646 A IL22646 A IL 22646A IL 2264664 A IL2264664 A IL 2264664A IL 22646 A IL22646 A IL 22646A
- Authority
- IL
- Israel
- Prior art keywords
- dicyclohexylmethyl
- carbonate
- prednisolone
- reacted
- product
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- 150000003126 pregnane derivatives Chemical class 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 23
- -1 dicyclohexylmethyl Chemical group 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229960005205 prednisolone Drugs 0.000 claims description 8
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004544 cortisone Drugs 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- KQQSXFCECNBYCO-UHFFFAOYSA-N dicyclohexylmethyl hydrogen carbonate Chemical compound C1CCCCC1C(OC(=O)O)C1CCCCC1 KQQSXFCECNBYCO-UHFFFAOYSA-N 0.000 claims 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 claims 1
- 239000000047 product Substances 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DEFUSPNGFCCTEU-UHFFFAOYSA-N dicyclohexylmethanol Chemical compound C1CCCCC1C(O)C1CCCCC1 DEFUSPNGFCCTEU-UHFFFAOYSA-N 0.000 description 1
- GAIBLEBDNVIFQC-UHFFFAOYSA-N dicyclohexylmethyl carbonochloridate Chemical compound C1CCCCC1C(OC(=O)Cl)C1CCCCC1 GAIBLEBDNVIFQC-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR957778A FR3244M (fr) | 1963-12-19 | 1963-12-19 | Nouveau médicament notamment pour le traitement des manifestations inflammatoires d'origine rhumatismale, arthritique ou infectieuse. |
| FR959162A FR4053M (de) | 1963-12-19 | 1964-01-02 | |
| FR965895A FR1512323A (fr) | 1963-12-19 | 1964-03-03 | Nouveaux esters en 21 de dérivés cortisoniques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL22646A true IL22646A (en) | 1968-12-26 |
Family
ID=27247656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL22646A IL22646A (en) | 1963-12-19 | 1964-12-18 | 21-esters of pregnane derivatives and a process for their preparation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3329570A (de) |
| BE (1) | BE657318A (de) |
| BR (1) | BR6465427D0 (de) |
| CH (1) | CH437276A (de) |
| DE (1) | DE1468893C3 (de) |
| DK (1) | DK112235B (de) |
| FR (3) | FR3244M (de) |
| GB (1) | GB1068099A (de) |
| IL (1) | IL22646A (de) |
| NL (2) | NL6414703A (de) |
| SE (1) | SE317971B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2462443A1 (fr) * | 1979-07-26 | 1981-02-13 | Roussel Uclaf | Nouveau derive halogene de la serie du 16a-methyl pregnane, son procede de preparation et son application comme medicament |
| US7306559B2 (en) * | 1997-07-02 | 2007-12-11 | Lumitex, Inc. | Illuminated surgical retractor |
| AU2003217535A1 (en) * | 2002-02-20 | 2003-09-09 | Sepracor Inc. | Carbonate and carbamate modified forms of glucocorticoids |
| US20050009798A1 (en) * | 2002-02-20 | 2005-01-13 | Sepracor Inc. | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3105083A (en) * | 1960-04-14 | 1963-09-24 | Upjohn Co | 21-organic sulfonates of 11, 17, 21-trioxygenated-3-keto pregnenes |
| US3056727A (en) * | 1960-10-27 | 1962-10-02 | Roussel Uclaf | Cyclohexylcarbonates of steroids |
-
0
- NL NL122815D patent/NL122815C/xx active
-
1963
- 1963-12-19 FR FR957778A patent/FR3244M/fr not_active Expired
-
1964
- 1964-01-02 FR FR959162A patent/FR4053M/fr not_active Expired
- 1964-03-03 FR FR965895A patent/FR1512323A/fr not_active Expired
- 1964-12-15 DE DE1468893A patent/DE1468893C3/de not_active Expired
- 1964-12-17 NL NL6414703A patent/NL6414703A/xx unknown
- 1964-12-17 BR BR165427/64A patent/BR6465427D0/pt unknown
- 1964-12-18 US US419556A patent/US3329570A/en not_active Expired - Lifetime
- 1964-12-18 DK DK621964AA patent/DK112235B/da unknown
- 1964-12-18 IL IL22646A patent/IL22646A/en unknown
- 1964-12-18 SE SE15420/64A patent/SE317971B/xx unknown
- 1964-12-18 BE BE657318A patent/BE657318A/xx unknown
- 1964-12-18 CH CH1636064A patent/CH437276A/fr unknown
- 1964-12-21 GB GB5183/64A patent/GB1068099A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CH437276A (fr) | 1967-06-15 |
| FR1512323A (fr) | 1968-02-09 |
| GB1068099A (en) | 1967-05-10 |
| NL6414703A (de) | 1965-06-21 |
| NL122815C (de) | |
| SE317971B (de) | 1969-12-01 |
| BE657318A (de) | 1965-06-18 |
| BR6465427D0 (pt) | 1973-08-07 |
| DE1468893B2 (de) | 1975-05-15 |
| DE1468893C3 (de) | 1976-01-02 |
| FR3244M (fr) | 1965-04-12 |
| US3329570A (en) | 1967-07-04 |
| DK112235B (da) | 1968-11-25 |
| DE1468893A1 (de) | 1972-04-27 |
| FR4053M (de) | 1966-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3234246A (en) | delta1-3, 11, 20-triketo-17alpha-hydroxy-21-lower alkanoyloxy-4-bromo-pregnene | |
| US3478070A (en) | Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof | |
| US3312591A (en) | Topical compositions of 17alpha,21-ortho esters of betamethasone having topical anti-inflammatory activity and their use | |
| US3383394A (en) | Novel 17-acylating process and products thereof | |
| IL22646A (en) | 21-esters of pregnane derivatives and a process for their preparation | |
| US3328432A (en) | Novel progesterone derivatives | |
| US3865848A (en) | Methylenation reagent | |
| US2892851A (en) | 11-oxygenated derivatives of 9-fluoro-17-acyloxyprogesterones | |
| US2963498A (en) | Dehydro derivatives of 11-oxygenated 17alpha-(lower alkanoyl)-oxy-9alpha-halopregnane-3, 20-diones | |
| US2389325A (en) | Process for the manufacture of alpha-hydroxycarbonyl compounds | |
| US2345711A (en) | Sterol compound and method of obtaining the same | |
| US2948740A (en) | 2-hydroxy-delta1, 4-steroids | |
| US2873271A (en) | 1, 4, 17(20)-pregnatrienes | |
| GB2079754A (en) | Production of 16-methyl-17 -acyloxy corticoids by selective solvolysis of 11-trihaloacetoxy and 21-acyloxy groups | |
| US3185713A (en) | 12-keto progestational steroids and derivatives thereof | |
| US2873285A (en) | -pregnatrienes | |
| US3143557A (en) | Substituted 19-norandrosta-5(10), 9(11)-dienes and method of preparing same | |
| US3280114A (en) | 17-lowerr alkyl ethers of 6-chloro-delta4, 6-pregnadien-17alpha-ol-3, 20-dione | |
| US3301850A (en) | 17-oxygenated-5alpha-androstane-2alpha, 3alpha-episulfides | |
| US2749356A (en) | Method of isolating and purifying keto steroids and new keto steroid compounds | |
| US3118919A (en) | Dienic steroids and method of preparing the same | |
| US3448126A (en) | 3-oxygenated 19-norpregna-1,3,5(10),17(20)-tetraen-21-als and enol esters thereof | |
| US3314977A (en) | Optionally 17alpha-alkylated 3-oxygenated 2alpha-dialkylaminomethyl-5alpha-androstan-17beta-ols and esters thereof | |
| US2873284A (en) | N, n-dialkyl acylamide solvate of 1, 4-pregnadiene-17alpha, 21-diol-3, 11, 20-trione-21-acylate and process of preparing such | |
| US3254100A (en) | Hydrocortisone 21-(lower alkane) sulfonate |